Order Entry
United States
ContactUsLinkComponent
Human Recombinant CD160 (from CHO cells)
Human Recombinant CD160 (from CHO cells)
Catalog # 102981-496
Supplier:  Adipogen
CAS Number:  
Human Recombinant CD160 (from CHO cells)
Catalog # 102981-496
Supplier:  Adipogen
Supplier Number:  CHI-HF-210CD160-C100
CAS Number:  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

Specifications

  • Conjugation:
    Unconjugated
  • Protein/Peptide Type:
    Recombinant
  • Source:
    CHO cells
  • Species:
    Human
  • Size:
    100 µg
  • Storage Conditions:
    –20 °C
  • Endotoxin Content:
    <0.06EU/µg
  • Biological Activity:
    Measured by its binding ability in a functional ELISA.
  • Gene ID:
    NP_008984.1
  • Protein Synonyms:
    NK28|NK1|Natural Killer Cell Receptor BY55
  • Protein/Peptide Name:
    CD160
  • Purity:
    98%
  • Endotoxin Level:
    Low
  • Formulation:
    Lyophilized from 0.2µm-filtered solution in PBS.
  • Shipping Temperature:
    -20 °C, Blue Ice
  • Cat. No.:
    102981-496
  • Supplier no.:
    HF210CD160C100

Specifications

About this item

CD160 is a GPI-anchored lymphocyte surface receptor in which expression is mostly restricted to the highly cytotoxic CD56(dim) CD16(+) peripheral blood NK subset. CD160 is a receptor showing broad specificity for both classical and non-classical MHC class I molecules. CD160 acts as a co-activator receptor for CD3-induced proliferation of CD4+ CD160+ T cells isolated from inflammatory skin lesions. CD160-Fc fusion protein targets a novel costimulatory pathway and prolongs allograft survival.